| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CRSDA; IL-11 receptor subunit alpha; IL-11R subunit alpha; IL11RA; Interleukin 11 receptor alpha; Interleukin 11 receptor alpha chain;;IL 11 receptor alpha |
| WB Predicted band size | 45 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthesized peptide derived from human IL 11 receptor alpha |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于IL11RA抗体的3篇参考文献示例(注：文献为示例性内容，实际引用需核实真实来源)：
---
1. **标题**：*"Neutralizing anti-IL11RA antibodies inhibit stromal proliferation and improve chemotherapy response in pancreatic cancer"*
**作者**：Chen, L. et al.
**摘要**：研究报道了一种中和性IL11RA抗体通过阻断IL11信号通路，抑制胰腺癌模型中的肿瘤微环境纤维化，增强化疗药物吉西他滨的疗效。
2. **标题**：*"Structural basis of IL-11 recognition by IL-11RA and antibody-mediated receptor antagonism"*
**作者**：Wang, Y. et al.
**摘要**：通过冷冻电镜解析IL11与IL11RA的复合物结构，并开发了一种人源化抗体，该抗体通过竞争性结合受体胞外域阻断下游STAT3信号传导，为治疗纤维化疾病提供策略。
3. **标题**：*"IL11RA-targeted antibody therapy reduces bone metastasis in breast cancer models"*
**作者**：Tanaka, R. et al.
**摘要**：在小鼠模型中，靶向IL11RA的单克隆抗体显著抑制乳腺癌细胞向骨组织的转移，机制涉及抑制破骨细胞活化和肿瘤-微环境互作。
---
建议通过PubMed或Google Scholar搜索真实文献，使用关键词“IL11RA antibody therapy”或“IL11RA blockade”获取最新研究。
The interleukin-11 receptor alpha (IL11RA) is a key subunit of the IL11 receptor complex, a member of the type I cytokine receptor family. It binds interleukin-11 (IL11), a pleiotropic cytokine involved in regulating inflammation, tissue repair, and cellular processes such as proliferation and differentiation. IL11RA pairs with the glycoprotein 130 (gp130) co-receptor to activate downstream signaling pathways, including JAK/STAT, MAPK, and PI3K/AKT, which influence immune responses, fibrosis, and cancer progression. Dysregulation of IL11/IL11RA signaling is linked to fibrotic diseases (e.g., pulmonary fibrosis), inflammatory disorders, and malignancies, making it a therapeutic target.
IL11RA antibodies are tools designed to block IL11-IL11RA interactions or modulate receptor activity. Monoclonal antibodies (mAbs) against IL11RA are widely used in research to dissect the cytokine’s role in disease models, while therapeutic antibodies aim to inhibit pathological signaling. For example, preclinical studies suggest that anti-IL11RA agents reduce fibrosis and tumor growth by disrupting IL11-mediated pro-survival and pro-fibrotic signals. Some antibodies also serve as diagnostic markers to assess IL11RA expression in tissues, correlating with disease severity in certain cancers. Despite promising data, clinical translation remains limited, with most applications still in experimental phases. Ongoing research focuses on optimizing antibody specificity and minimizing off-target effects to harness IL11RA blockade for treating chronic fibrotic diseases and inflammation-driven cancers.
×
